Skip to main content
OpenTrials
Completed

NCT Number: NCT01743222

Intralymphatic eASC Administration in Healthy Volunteers

The objective is to determine the safety, tolerability and feasibility of the inguinal intralymphatic administration of expanded allogeneic adipose-derived stem cells (eASCs)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Unidad de Investigación Clínica de la Clínica Universidad de Navarra

Pamplona, 31008, Spain

About this study

Phase I, unicentric, single blind, clinical trial with healthy volunteers to determine the feasibility of a new administration technique.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 55 both included
  • Inform Consent Form signed
  • Body Mass Index (BMI) between 19 and 29 kg/m2
  • Presence of, at least, one lymph node of 1cm in its larger diameter in each inguinal location. It has to be accessible for administration after its localization using ultrasound scan.

Exclusion criteria

  • Pregnant (positive to urine pregnancy test) or breastfeeding women.
  • Subjects with history of any organic or psychic pathology in their records, physical exploration or any complementary test.
  • Any relevant current pathology, including cancer, liver pathology, gastrointestinal dysfunction, renal alteration, respiratory pathology or active acute infectious problems.
  • Chronic disorders or previous recurrent like hypertension, infections, cardiovascular, respiratory, endocrine, neurologic, hematologic, renal or liver disorders.
  • Subjects treated four weeks before the first administration with any drug, medicinal plant or Consumer Health Care in a continue routine. It is not consider exclusion criteria a sporadic medication. The physician will study the interaction between the eASC with this medication.
  • History of hypersensibility to drugs.
  • Volunteers participants in other clinical trial within 4 months prior the start of the study.
  • Blood or derivatives transfusion in 6 months before the trial.
  • Known history of abuse of alcohol or other addictive substances(amount of alcohol allow as maximum in this trial is 0.5 liter of wine or two beers or amount in grams equivalent to this of any other alcoholic drink).
  • Illegal drugs consumption during the month before the enrollment in the study or positive result to a drug test.
  • Positive serology for B hepatitis virus (HbsAg), C hepatitis virus or HIV (Human Inmunodeficiency Virus).
  • Subjects whose freedom depends on legal or administrative requirements.

Treatment and study plan

eASC

Genetic
  • First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.
  • Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells.

Other names: Allogenic Stem Cells

Placebo

Drug
  • First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node
  • Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node

Other names: HypoThermosol HTS

Primary outcomes

  1. Local and systemic reaction to administration procedure

    Time frame: 29 days

    • Pain in administration area will be assessed by a visual analogical scale.
    • Medical exploration of the administration area will be performed to identify any skin reaction.
    • Inguinal scan will be performed to assess any lymphatic node modification.
    • Systemic tolerability will be measured by number of AE (Adverse Event) recorded at any time, including any alteration in laboratory parameters and/or physical exploration.

Secondary outcomes

  1. Pharmacodynamic parameters

    Time frame: 29 days

    • Detection of reactive cells and antibodies against eASC
    • Lymphocyte subpopulations studies

Sponsors and collaborators

Lead sponsor

Tigenix S.A.U.

Industry

Registry information

Official study title

Cx621-0101 Phase I Clinical Trial in Healthy Volunteers to Evaluate the Feasibility and Safety of the Intralymphatic Administration Technique of Expanded Allogeneic Adipose-derived Stem Cells (eASCs)

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Dec 6, 2012
Registry last updated
Apr 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.